	US 12,226,422 B2
	Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
Frank Löscher, Schriesheim (DE); Diana Strehl, Heidelberg (DE); and Kirsten Eickhoff, Aschaffenburg (DE)
Assigned to NOVALIQ GMBH, Heidelberg (DE)
Appl. No. 17/051,016
Filed by NOVALIQ GMBH, Heidelberg (DE)
PCT Filed Apr. 24, 2019, PCT No. PCT/EP2019/060455 § 371(c)(1), (2) Date Oct. 27, 2020, PCT Pub. No. WO2019/206956, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 18169920 (EP), filed on Apr. 27, 2018.
Prior Publication US 2021/0228595 A1, Jul. 29, 2021
Int. Cl. A61K 31/5575 (2006.01); A61F 9/00 (2006.01); A61K 9/00 (2006.01); A61K 31/02 (2006.01); A61P 27/06 (2006.01)

CPC A61K 31/5575 (2013.01) [A61F 9/0008 (2013.01); A61K 9/0048 (2013.01); A61K 31/02 (2013.01); A61P 27/06 (2018.01)]

19 Claims

1. A method of treating glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, comprising administering to a patient in need thereof, a pharmaceutical composition consisting of 0.002-0.005% (w/v) tafluprost dissolved in a vehicle consisting of a semifluorinated alkane and up to 3% (w/w) of ethanol.